These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 33062062)

  • 1. FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules.
    Foschini F; Napolitano F; Servetto A; Marciano R; Mozzillo E; Carratù AC; Santaniello A; De Placido P; Cascetta P; Butturini G; Frigerio I; Regi P; Silvestris N; Delcuratolo S; Vasile E; Vivaldi C; Bianco C; De Placido S; Formisano L; Bianco R
    Ther Adv Med Oncol; 2020; 12():1758835920947970. PubMed ID: 33062062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma.
    Kim G; Cockrum P; Surinach A; Wang S; Wainberg Z
    Curr Med Res Opin; 2022 Aug; 38(8):1295-1303. PubMed ID: 35354375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOLFOX vs FOLFIRI as Second-line of Therapy After Progression to Gemcitabine/Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer.
    Catalano M; Conca R; Petrioli R; Ramello M; Roviello G
    Cancer Manag Res; 2020; 12():10271-10278. PubMed ID: 33116881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOLFIRINOX De-Escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study.
    Chevalier H; Vienot A; Lièvre A; Edeline J; El Hajbi F; Peugniez C; Vernerey D; Meurisse A; Hammel P; Neuzillet C; Borg C; Turpin A
    Oncologist; 2020 Nov; 25(11):e1701-e1710. PubMed ID: 32886823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study).
    Giommoni E; Maiello E; Vaccaro V; Rondini E; Vivaldi C; Tortora G; Toppo L; Giordano G; Latiano TP; Lamperini C; Pillozzi S; Boni L; Antonuzzo L; Di Costanzo F
    Curr Oncol; 2021 May; 28(3):1761-1772. PubMed ID: 34066784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI/FOLFOX) as a second-line treatment regimen for unresectable pancreatic cancer: A real-world analysis.
    Tezuka S; Ueno M; Oishi R; Nagashima S; Sano Y; Kawano K; Tanaka S; Fukushima T; Asama H; Konno N; Kobayashi S; Morimoto M; Maeda S
    Cancer Med; 2022 Feb; 11(4):1088-1098. PubMed ID: 34953056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG).
    Park HS; Kang B; Chon HJ; Im HS; Lee CK; Kim I; Kang MJ; Hwang JE; Bae WK; Cheon J; Park JO; Hong JY; Kang JH; Kim JH; Lim SH; Kim JW; Kim JW; Yoo C; Choi HJ
    ESMO Open; 2021 Apr; 6(2):100049. PubMed ID: 33578192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOLFIRI-bevacizumab as a second-line treatment for advanced biliary tract cancer after gemcitabine-based chemotherapy.
    Roussot N; Vincent J; Palmier R; Constantin G; Bengrine L; Fumet JD; Ghiringhelli F
    Front Oncol; 2023; 13():1293670. PubMed ID: 38098503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.
    Kang BW; Kim TW; Lee JL; Ryu MH; Chang HM; Yu CS; Kim JC; Kim JH; Kang YK; Lee JS
    Med Oncol; 2009; 26(1):32-7. PubMed ID: 18498064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study.
    Zaanan A; Trouilloud I; Markoutsaki T; Gauthier M; Dupont-Gossart AC; Lecomte T; Aparicio T; Artru P; Thirot-Bidault A; Joubert F; Fanica D; Taieb J
    BMC Cancer; 2014 Jun; 14():441. PubMed ID: 24929865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of FOLFIRINOX Chemotherapy with Other Regimens in Patients with Biliary Tract Cancers: a Retrospective Study.
    Kus T; Aktas G; Kalender ME; Sevinc A; Camci C
    J Gastrointest Cancer; 2017 Jun; 48(2):170-175. PubMed ID: 27714651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen.
    Sendur MA; Ozdemir N; Özatlı T; Yazıcı O; Aksoy S; Ekinci AS; Yazılıtaş D; Günaydın Y; Oksuzoglu B; Benekli M; Zengin N
    Med Oncol; 2014 Sep; 31(9):153. PubMed ID: 25099765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
    Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
    Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study.
    Bendell JC; Bekaii-Saab TS; Cohn AL; Hurwitz HI; Kozloff M; Tezcan H; Roach N; Mun Y; Fish S; Flick ED; Dalal D; Grothey A
    Oncologist; 2012; 17(12):1486-95. PubMed ID: 23015662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of oxaliplatin combined with 5-fluorouracil and folinic acid in the first- and second-line treatment of advanced colorectal cancer.
    Jonker D; Rumble RB; Maroun J;
    Curr Oncol; 2006 Oct; 13(5):173-84. PubMed ID: 22792014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer.
    Muranaka T; Kuwatani M; Komatsu Y; Sawada K; Nakatsumi H; Kawamoto Y; Yuki S; Kubota Y; Kubo K; Kawahata S; Kawakubo K; Kawakami H; Sakamoto N
    J Gastrointest Oncol; 2017 Jun; 8(3):566-571. PubMed ID: 28736643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modified FOLFIRINOX for unresectable locally advanced/metastatic pancreatic cancer. A real-world comparison of an attenuated with a full dose in a single center experience.
    Cavanna L; Stroppa EM; Citterio C; Mordenti P; Di Nunzio C; Peveri S; Orlandi E; Vecchia S
    Onco Targets Ther; 2019; 12():3077-3085. PubMed ID: 31118666
    [No Abstract]   [Full Text] [Related]  

  • 18. Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study).
    Moriwaki T; Bando H; Takashima A; Yamazaki K; Esaki T; Yamashita K; Fukunaga M; Miyake Y; Katsumata K; Kato S; Satoh T; Ozeki M; Baba E; Yoshida S; Boku N; Hyodo I
    Med Oncol; 2012 Dec; 29(4):2842-8. PubMed ID: 22209842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
    Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
    Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative Dose Intensity of Chemotherapy and Survival in Patients with Advanced Stage Solid Tumor Cancer: A Systematic Review and Meta-Analysis.
    Nielson CM; Bylsma LC; Fryzek JP; Saad HA; Crawford J
    Oncologist; 2021 Sep; 26(9):e1609-e1618. PubMed ID: 33973301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.